Subscribe

NEXGEL, Inc. (NXGL)

USD0.46 -0.01 (-2.73%)
US NASDAQ Healthcare Medical - Instruments & Supplies
Address 2150 Cabot Boulevard West 19047
Langhorne, PA, US
CEO Adam R. Levy
Website nexgel.com
IPO 2021-12-22
CIK 1468929 ISIN US65344E1073

Explore sections of this company profile

Also trades on NASDAQ Capital Market · NXGL (USD) NASDAQ Capital Market · NXGLW (USD)
Description

NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.46 -0.01 (-2.73%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
340.3K
Beta
0.76
Float Shares
8.53M
Free Float %
80.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.69% -11.15% -8.86% -58.31% -71.62% -66.34% -78.41% -65.23% -84.60% -84.60% -84.60%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (1 ratings, all time) Buy
Price Targets & DCF
Current price
0.46
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-1.85
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +31.5% ★ Q1'26: -5.6% (vs Q1'25)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    +24.0% ★ Q1'26: -18.2% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    -15.4% Q1'26: -19.4% (vs Q1'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    -25.0% Q1'26: +0.0% (vs Q1'25)
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    -37.3% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +20.6% Q1'26: +7.3% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    -1.46× Q1'26: -1.09× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.74) × ERP
WACC = 60% × Ke + 40% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.46
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
1.55M
est: 1.44M (+7.9%)
2.05M
est: 2.12M (-3.4%)
4.09M
est: 4.11M (-0.4%)
8.69M
est: 8.64M (+0.6%)
11.42M
est: 11.86M (-3.7%)
32.61M
32.61M – 32.61M
+174.9% YoY
41.76M
41.76M – 41.76M
+28.0% YoY
45.84M
45.84M – 45.84M
+9.8% YoY
50.45M
50.45M – 50.45M
+10.1% YoY
54.20M
54.20M – 54.20M
+7.4% YoY
EBITDA
-2.17M
est: -1.15M (-88.9%)
-3.11M
est: -1.70M (-83.2%)
-2.73M
est: -3.29M (+16.9%)
-2.90M
est: -5.51M (+47.3%)
-2.12M
est: -7.56M (+72.0%)
-20.79M
-20.79M – -20.79M
-174.9% YoY
-26.62M
-26.62M – -26.62M
-28.0% YoY
-29.22M
-29.22M – -29.22M
-9.8% YoY
-32.16M
-32.16M – -32.16M
-10.1% YoY
-34.55M
-34.55M – -34.55M
-7.4% YoY
EBIT
-2.31M
est: -1.20M (-93.0%)
-3.41M
est: -1.77M (-93.0%)
-3.17M
est: -3.42M (+7.3%)
-3.38M
est: -5.90M (+42.7%)
-2.86M
est: -8.10M (+64.7%)
-22.28M
-22.28M – -22.28M
-174.9% YoY
-28.53M
-28.53M – -28.53M
-28.0% YoY
-31.31M
-31.31M – -31.31M
-9.8% YoY
-34.46M
-34.46M – -34.46M
-10.1% YoY
-37.02M
-37.02M – -37.02M
-7.4% YoY
Net Income
-4.31M
est: -325.6K (-1,223.8%)
-4.75M
est: -5.73M (+17.2%)
-3.16M
est: -3.06M (-3.2%)
-3.28M
est: -4.24M (+22.6%)
-3.00M
est: -2.75M (-9.1%)
2.91M
2.91M – 2.91M
+205.7% YoY
6.44M
6.44M – 6.44M
+121.6% YoY
4.01M
4.01M – 4.01M
-37.8% YoY
4.79M
4.79M – 4.79M
+19.6% YoY
5.18M
5.18M – 5.18M
+8.2% YoY
SGA
2.41M
est: 2.12M (+13.6%)
2.82M
est: 3.12M (-9.8%)
3.40M
est: 6.04M (-43.8%)
5.91M
est: 8.85M (-33.2%)
7.86M
est: 12.16M (-35.4%)
33.43M
33.43M – 33.43M
+174.9% YoY
42.80M
42.80M – 42.80M
+28.0% YoY
46.99M
46.99M – 46.99M
+9.8% YoY
51.71M
51.71M – 51.71M
+10.1% YoY
55.56M
55.56M – 55.56M
+7.4% YoY
EPS
-0.77
est: -0.05 (-1,440.0%)
-0.85
est: -0.88 (+3.4%)
-0.56
est: -0.47 (-19.1%)
-0.50
est: -0.54 (+7.4%)
-0.38
est: -0.35 (-8.6%)
0.37
0.37 – 0.37
+205.7% YoY
0.82
0.82 – 0.82
+121.6% YoY
0.51
0.51 – 0.51
-37.8% YoY
0.61
0.61 – 0.61
+19.6% YoY
0.66
0.66 – 0.66
+8.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-11 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-07 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-06 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-05 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-04 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-01 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-30 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
452.5K
OE per share TTM
0.06
Owner's Yield
9.93%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
64.5%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
20
Total invested
970.6K
Insider transactions (90d)
2
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2025 Q4
Investors holding
20
+3 vs prev Q
New positions
5
Closed positions
2
Increased
9
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 VANGUARD GROUP INC 123.1K -548.0 (-0.4%) 198.1K -103.5K (-34.3%) 1.54% -0.071 pp 0.00% +0.000 pp USD2.41 -33.2% 10 qtrs —
2 MORGAN STANLEY 85.4K -1.7K (-2.0%) 137.5K -75.0K (-35.3%) 1.07% -0.067 pp 0.00% +0.000 pp USD3.91 -58.8% 17 qtrs —
3 GEODE CAPITAL MANAGEMENT, LLC 67.0K +667.0 (+1.0%) 108.0K -54.0K (-33.4%) 0.84% -0.026 pp 0.00% +0.000 pp USD2.61 -38.3% 11 qtrs —
4 CITADEL ADVISORS LLC 60.2K +32.8K (+119.4%) 97.0K +30.0K (+44.8%) 0.76% +0.397 pp 0.00% +0.000 pp USD1.99 -19.1% 2 qtrs —
5 RENAISSANCE TECHNOLOGIES LLC 55.3K -8.1K (-12.8%) 89.0K -65.8K (-42.5%) 0.69% -0.135 pp 0.00% 0.000 pp USD3.79 -57.5% 15 qtrs —
6 SIMON QUICK ADVISORS, LLC 35.7K +— (+0.0%) 57.5K -29.6K (-34.0%) 0.45% -0.019 pp 0.00% -0.001 pp USD1.70 -5.3% 15 qtrs —
7 BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 32.5K +32.5K (+100.0%) 52.3K +52.3K (+100.0%) 0.41% +0.408 pp 0.01% +0.011 pp USD1.61 +0.0% 1 qtrs NEW
8 SUSQUEHANNA INTERNATIONAL GROUP, LLP 30.2K -13.4K (-30.7%) 48.7K -57.8K (-54.3%) 0.38% -0.191 pp 0.00% +0.000 pp USD2.44 -34.0% 2 qtrs —
9 JANE STREET GROUP, LLC 29.5K +29.5K (+100.0%) 47.4K +47.4K (+100.0%) 0.37% +0.370 pp 0.00% +0.000 pp USD1.61 +0.0% 1 qtrs NEW
10 FLAHARTY ASSET MANAGEMENT, LLC 24.0K +— (+0.0%) 38.6K -19.9K (-34.0%) 0.30% -0.013 pp 0.00% -0.003 pp USD2.90 -44.5% 4 qtrs —
11 STATE STREET CORP 17.3K +— (+0.0%) 27.8K -14.3K (-34.0%) 0.22% -0.009 pp 0.00% +0.000 pp USD4.46 -63.9% 5 qtrs —
12 XTX TOPCO LTD 15.0K +1.9K (+14.7%) 24.1K -7.8K (-24.3%) 0.19% +0.017 pp 0.00% -0.001 pp USD2.71 -40.6% 4 qtrs —
13 MALAGA COVE CAPITAL, LLC 13.4K +13.4K (+100.0%) 21.6K +21.6K (+100.0%) 0.17% +0.168 pp 0.01% +0.008 pp USD1.61 +0.0% 3 qtrs —
14 IFP ADVISORS, INC 11.0K +— (+0.0%) 17.7K -9.1K (-34.0%) 0.14% -0.006 pp 0.00% 0.000 pp USD3.72 -56.7% 5 qtrs —
15 TOWER RESEARCH CAPITAL LLC (TRC) 1.9K +1.9K (+100.0%) 3.0K +3.0K (+100.0%) 0.02% +0.024 pp 0.00% +0.000 pp USD1.61 +0.0% 1 qtrs NEW
16 CITIGROUP INC 995.00 +995.0 (+100.0%) 1.6K +1.6K (+100.0%) 0.01% +0.013 pp 0.00% +0.000 pp USD1.61 +0.0% 1 qtrs NEW
17 ADVISOR GROUP HOLDINGS, INC. 305.00 +— (+0.0%) 491.00 -253.0 (-34.0%) 0.00% 0.000 pp 0.00% +0.000 pp USD2.58 -37.6% 6 qtrs —
18 BANK OF AMERICA CORP /DE/ 61.00 +1.0 (+1.7%) 98.00 -49.0 (-33.3%) 0.00% +0.000 pp 0.00% +0.000 pp USD2.23 -27.8% 7 qtrs —
19 SBI SECURITIES CO., LTD. 7.00 +— (+0.0%) 11.00 -6.0 (-35.3%) 0.00% +0.000 pp 0.00% +0.000 pp USD4.43 -63.7% 5 qtrs —
20 UBS GROUP AG 2.00 -344.0 (-99.4%) 3.00 -841.0 (-99.6%) 0.00% -0.005 pp 0.00% +0.000 pp USD2.00 -19.5% 3 qtrs —
21 DIMENSIONAL FUND ADVISORS LP — -10.5K (-100.0%) — -25.7K (-100.0%) 0.00% -0.138 pp 0.00% +0.000 pp USD— 2 qtrs SOLD
22 ESSEX INVESTMENT MANAGEMENT CO LLC — -38.0K (-100.0%) — -92.8K (-100.0%) 0.00% -0.497 pp 0.00% -0.014 pp USD— 4 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Vanguard Extended Market ETF VXF 0.00% 28.7K 0.05%
2 U.S. Micro Cap Portfolio ETF DFMC 0.00% 103.67 0.43%
3 Dimensional - US Small Cap ETF DFAS 0.00% 73.84 0.26%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
5
Shares acquired
—
Shares disposed
16.0K
Cash buys
—
Cash sales
5.00
Net activity
-16,000
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-04-27 Blackman Ian Howard Officer — — Stock Option (right to buy) 160,000 0.65 104.0K 0 D ↗
2026-04-17 Blackman Ian Howard Officer — — $25,000 Convertible Note (right to buy) 41,667 0.60 25.0K 0 D ↗
2025-12-24 Levy Adam R. Director / Officer S-Sale D Common Stock 4,000 1.57 6.3K 357,692 D ↗
2025-12-22 Levy Adam R. Director / Officer S-Sale D Common Stock 6,000 1.61 9.7K 361,692 D ↗
2025-11-06 Levy Adam R. Director / Officer S-Sale D Common Stock 4,000 2.52 10.1K 367,692 D ↗
2025-10-03 Levy Adam R. Director / Officer S-Sale D Common Stock 2,400 2.55 6.1K 371,692 D ↗
2025-10-03 Henry Scott Robert Director S-Sale D Common Stock 7,175 2.55 18.3K 113,356 D ↗
2025-10-02 Levy Adam R. Director / Officer S-Sale D Common Stock 1,600 2.50 4.0K 374,092 D ↗
2025-10-02 Henry Scott Robert Director S-Sale D Common Stock 825 2.50 2.1K 120,531 D ↗
2025-09-25 Henry Scott Robert Director S-Sale D Common Stock 7,697 2.36 18.1K 121,356 D ↗
2025-08-28 Levy Adam R. Director / Officer S-Sale D Common Stock 4,000 2.47 9.9K 358,284 D ↗
2025-07-31 Ciardiello Steven Director — — Common Stock 0 0.00 — 21,739 D ↗
2025-06-25 glassman steven mark Director A-Award A Stock Option(Right to Buy) 30,000 2.32 69.6K 30,000 D ↗
2025-06-25 ZELDIS JEROME B Director A-Award A Stock Option (Right to Buy) 30,000 2.32 69.6K 30,000 D ↗
2025-06-25 Stein John Nachum Director A-Award A Stock Option (Right to Buy) 30,000 2.32 69.6K 30,000 D ↗
2025-06-25 Henry Scott Robert Director A-Award A Restricted Stock Units 5,000 0.00 — 5,000 D ↗
2025-06-13 Henry Scott Robert Director S-Sale D Common Stock 3,000 2.57 7.7K 129,053 D ↗
2025-06-11 Levy Adam R. Director / Officer S-Sale D Common Stock 2,000 2.39 4.8K 362,284 D ↗
2025-06-09 Levy Adam R. Director / Officer S-Sale D Common Stock 2,000 2.33 4.7K 364,284 D ↗
2025-06-05 Levy Adam R. Director / Officer S-Sale D Common Stock 1,000 2.32 2.3K 366,284 D ↗
2025-06-04 Levy Adam R. Director / Officer S-Sale D Common Stock 1,000 2.29 2.3K 367,284 D ↗
2025-05-30 Levy Adam R. Director / Officer S-Sale D Common Stock 1,000 2.22 2.2K 368,284 D ↗
2025-05-16 Levy Adam R. Director / Officer S-Sale D Common Stock 1,000 2.58 2.6K 369,284 D ↗
2025-05-12 Henry Scott Robert Director S-Sale D Common Stock 3,000 2.69 8.1K 132,053 D ↗
2025-04-10 Henry Scott Robert Director S-Sale D Common Stock 3,000 2.61 7.8K 135,053 D ↗
2025-04-01 Levy Adam R. Director / Officer S-Sale D Common Stock 4,000 3.01 12.0K 370,284 D ↗
2025-03-10 Henry Scott Robert Director S-Sale D Common Stock 3,000 2.87 8.6K 138,053 D ↗
2025-03-03 Levy Adam R. Director / Officer S-Sale D Common Stock 4,000 3.16 12.6K 374,284 D ↗
2025-02-12 glassman steven mark Director A-Award A Common Stock 2,500 0.00 — 156,655 D ↗
2025-02-12 Henry Scott Robert Director A-Award A Common Stock 2,500 0.00 — 141,053 D ↗
2025-02-10 Henry Scott Robert Director S-Sale D Common Stock 3,000 3.27 9.8K 138,553 D ↗
2025-02-03 Levy Adam R. Director / Officer S-Sale D Common Stock 4,000 3.64 14.6K 378,284 D ↗
2025-01-07 Henry Scott Robert Director S-Sale D Common Stock 3,000 3.37 10.1K 141,553 D ↗
2025-01-02 Levy Adam R. Director / Officer A-Award A Common Stock (restricted stock units) 26,116 0.00 — 386,284 D ↗
2025-01-01 MCGUIRE JOSEPH F Officer — — Common Stock 0 0.00 — 4,082 D ↗
2024-12-20 Henry Scott Robert Director S-Sale D Common Stock 3,000 4.64 13.9K 144,553 D ↗
2024-11-20 glassman steven mark Director P-Purchase A Common Stock 9,090 2.75 25.0K 154,155 D ↗
2024-11-20 ZELDIS JEROME B Director A-Award A Warrant to Purchase Common Stock 1,818 4.25 7.7K 1,818 D ↗
2024-11-20 Stein John Nachum Director P-Purchase A Common Stock 3,636 2.75 10.0K 471,456 D ↗
2024-11-20 Levy Adam R. Director / Officer P-Purchase A Common Stock 3,636 2.75 10.0K 333,196 D ↗
2024-11-20 Henry Scott Robert Director A-Award A Warrant to Purchase Common Stock 909 4.25 3.9K 909 D ↗
2024-11-20 Drapczuk Adam E III Officer A-Award A Warrant to Purchase Common Stock 8,750 4.25 37.2K 8,750 I ↗
2024-11-07 Stein John Nachum Director G-Gift D Common Stock 4,000 0.00 — 467,820 D ↗
2024-09-13 glassman steven mark Director A-Award A Stock Option (Right to Buy) 25,000 2.72 68.0K 25,000 — ↗
2024-09-13 ZELDIS JEROME B Director A-Award A Stock Option (Right to Buy) 25,000 2.72 68.0K 25,000 — ↗
2024-09-13 Stein John Nachum Director A-Award A Stock Option (Right to Buy) 25,000 2.72 68.0K 25,000 — ↗
2024-09-13 Henry Scott Robert Director A-Award A Stock Option (Right to Buy) 25,000 2.72 68.0K 25,000 — ↗
2024-08-23 glassman steven mark Director P-Purchase A Common Stock 10,000 2.50 25.0K 145,025 — ↗
2024-08-23 ZELDIS JEROME B Director P-Purchase A Common Stock 10,000 2.50 25.0K 103,028 — ↗
2024-08-23 Stein John Nachum Director P-Purchase A Common Stock 10,000 2.50 25.0K 471,820 — ↗
2024-08-23 Henry Scott Robert Director P-Purchase A Common Stock 10,000 2.50 25.0K 145,735 — ↗
2024-08-23 Drapczuk Adam E III Officer P-Purchase A Common Stock 10,000 2.50 25.0K 57,394 — ↗
2024-03-01 glassman steven mark Director P-Purchase A Common Stock 11,848 2.11 25.0K 135,025 — ↗
2024-03-01 Henry Scott Robert Director P-Purchase A Common Stock 23,697 2.11 50.0K 135,735 — ↗
2024-03-01 Drapczuk Adam E III Officer P-Purchase A Common Stock 47,394 2.11 100.0K 47,394 — ↗
2023-12-22 glassman steven mark Director P-Purchase A Common Stock 3,885 2.20 8.5K 123,177 — ↗
2023-09-26 Stein John Nachum Director P-Purchase A Common Stock 2,500 1.96 4.9K 500,019 — ↗
2023-09-14 Henry Scott Robert Director P-Purchase A Common Stock 500 2.27 1.1K 112,038 — ↗
2023-09-13 Henry Scott Robert Director P-Purchase A Common Stock 6,000 2.25 13.5K 111,538 — ↗
2023-09-12 Henry Scott Robert Director P-Purchase A Common Stock 4,000 2.28 9.1K 105,538 — ↗
2023-08-22 Henry Scott Robert Director P-Purchase A Common Stock 980 1.92 1.9K 101,538 — ↗
2023-08-21 Henry Scott Robert Director P-Purchase A Common Stock 2,000 1.95 3.9K 100,558 — ↗
2023-08-17 glassman steven mark Director A-Award A Stock Option (Right to Buy) 15,000 2.05 30.8K 15,000 — ↗
2023-08-17 ZELDIS JEROME B Director A-Award A Stock Option (Right to Buy) 15,000 2.05 30.8K 15,000 — ↗
2023-08-17 Toledano Miranda Jayne Director A-Award A Stock Option (Right to Buy) 15,000 2.05 30.8K 15,000 — ↗
2023-08-17 Stein John Nachum Director A-Award A Stock Option (Right to Buy) 15,000 2.05 30.8K 15,000 — ↗
2023-08-17 STEFANSKY DAVID Director A-Award A Stock Option (Right to Buy) 15,000 2.05 30.8K 15,000 — ↗
2023-08-17 Henry Scott Robert Director A-Award A Stock Option (Right to Buy) 15,000 2.05 30.8K 15,000 — ↗
2023-06-08 Stein John Nachum Director P-Purchase A Common Stock 5,000 2.28 11.4K 497,458 — ↗
2023-06-08 STEFANSKY DAVID Director P-Purchase A Common Stock 1,000 2.22 2.2K 50,091 — ↗
2023-06-08 Henry Scott Robert Director P-Purchase A Common Stock 3,558 2.24 8.0K 98,558 — ↗
2023-06-07 Stein John Nachum Director P-Purchase A Common Stock 5,000 2.69 13.5K 492,458 — ↗
2023-06-07 STEFANSKY DAVID Director P-Purchase A Common Stock 2,000 2.50 5.0K 49,091 — ↗
2023-06-02 Henry Scott Robert Director P-Purchase A Common Stock 2,000 2.40 4.8K 95,000 — ↗
2023-05-31 STEFANSKY DAVID Director P-Purchase A Common Stock 2,000 2.42 4.8K 47,091 — ↗
2023-05-31 Henry Scott Robert Director P-Purchase A Common Stock 1,000 2.25 2.3K 93,000 — ↗
2023-05-30 glassman steven mark Director P-Purchase A Common Stock 4,200 2.38 10.0K 119,292 — ↗
2023-05-30 STEFANSKY DAVID Director P-Purchase A Common Stock 5,000 2.53 12.7K 45,091 — ↗
2023-05-26 ZELDIS JEROME B Director P-Purchase A Common Stock 5,000 2.34 11.7K 93,028 — ↗
2023-05-24 Henry Scott Robert Director P-Purchase A Common Stock 2,000 2.01 4.0K 92,000 — ↗
2023-05-23 Henry Scott Robert Director P-Purchase A Common Stock 1,000 1.90 1.9K 90,000 — ↗
2023-05-22 Henry Scott Robert Director P-Purchase A Common Stock 4,000 1.95 7.8K 89,000 — ↗
2023-01-16 Henry Scott Robert Director — D Common Stock 0 0.00 — 85,000 — ↗
2022-12-19 STEFANSKY DAVID Director P-Purchase A Common Stock 5,000 1.59 8.0K 40,091 — ↗
2022-12-12 STEFANSKY DAVID Director P-Purchase A Common Stock 7,500 1.44 10.8K 35,091 — ↗
2022-11-29 STEIN NACHUM Director P-Purchase A Common Stock 3,000 1.17 3.5K 487,458 D ↗
2022-11-25 STEIN NACHUM Director P-Purchase A Common Stock 2,000 1.20 2.4K 484,458 D ↗
2022-11-23 STEIN NACHUM Director P-Purchase A Common Stock 100 1.20 120.00 483,458 D ↗
2022-11-21 STEIN NACHUM Director P-Purchase A Common Stock 2,000 1.17 2.3K 483,358 D ↗
2022-08-30 Spinrad Yaakov Director P-Purchase A Common Stock 1,648 1.68 2.8K 1,648 — ↗
2022-08-30 STEFANSKY DAVID Director P-Purchase A Common Stock 5,000 1.66 8.3K 27,591 — ↗
2022-08-25 STEFANSKY DAVID Director P-Purchase A Common Stock 5,000 1.73 8.7K 22,591 — ↗
2022-08-16 STEFANSKY DAVID Director P-Purchase A Common Stock 2,500 1.79 4.5K 17,591 — ↗
2022-08-15 STEFANSKY DAVID Director P-Purchase A Common Stock 2,872 1.90 5.5K 15,091 — ↗
2022-06-24 STEFANSKY DAVID Director P-Purchase A Common Stock 3,128 1.60 5.0K 12,219 — ↗
2022-05-27 Drapczuk Adam E III Officer P-Purchase A Common Stock 15,000 1.63 24.5K 15,000 — ↗
2022-03-25 glassman steven mark Director P-Purchase A Common Stock 5,500 1.87 10.3K 115,092 — ↗
2022-03-25 ZELDIS JEROME B Director P-Purchase A Common Stock 5,300 1.89 10.0K 88,028 — ↗
2022-03-25 STEIN NACHUM Director P-Purchase A Common Stock 5,000 1.90 9.5K 481,358 — ↗
2021-12-27 glassman steven mark Director A-Award A Warrant to Purchase Common Stock 5,000 5.50 27.5K 5,000 — ↗
2021-12-27 ZELDIS JEROME B Director A-Award A Warrant to Purchase Common Stock 9,091 5.50 50.0K 9,091 — ↗
2021-12-27 Toledano Miranda Jayne Director P-Purchase A Common Stock 1,819 5.49 10.0K 1,819 — ↗
2021-12-27 STEIN NACHUM Director P-Purchase A Common Stock 28,000 5.49 153.7K 476,358 — ↗
2021-12-27 STEFANSKY DAVID Director P-Purchase A Common Stock 9,091 5.49 49.9K 9,091 — ↗
2021-10-27 Levy Adam R. Director / Officer A-Award A Common Stock 1,428,750 0.00 — 10,295,529 — ↗
2021-10-01 Toledano Miranda Jayne Director — D Options to Purchase Common Stock 500,000 0.15 75.0K 0 — ↗
2021-10-01 Spinrad Yaakov Director — D Options to Purchase Common Stock 500,000 0.15 75.0K 0 — ↗
2021-06-01 Drapczuk Adam E III Officer — — — 0 0.00 — 0 — ↗
2021-03-08 glassman steven mark Director — D Common Stock 0 0.00 — 3,660,714 — ↗
2021-03-08 ZELDIS JEROME B Director A-Award A Option to Purchase Common Stock 666,667 0.06 40.0K 666,667 — ↗
2021-03-08 Levy Adam R. Officer / 10% Owner A-Award A Restricted Stock Award (Common Stock) 1,383,333 0.00 — 1,383,333 — ↗
2020-05-29 STEIN NACHUM Director J-Other A Common Stock 3,187,500 0.04 127.5K 4,822,500 — ↗
2020-05-29 Levy Adam R. Officer J-Other A Common Stock 1,546,875 0.04 61.9K 1,554,875 — ↗
2020-02-17 STEIN NACHUM Director A-Award A Option to Purchase Common Stock 2,857,141 0.01 40.0K 2,857,141 — ↗
2020-02-17 STEFANSKY DAVID Director A-Award A Option to Purchase Common Stock 2,857,141 0.01 40.0K 2,857,141 — ↗
2020-02-17 Levy Adam R. Officer A-Award A Restricted Stock Award (Common Stock) 5,928,571 0.00 — 5,928,571 — ↗
2019-09-10 STEIN NACHUM Director / 10% Owner — D Common Stock 0 0.00 — 1,634,750 — ↗
2019-09-10 STEFANSKY DAVID Director / 10% Owner — I Common Stock 0 0.00 — 1,634,750 — ↗
2019-09-10 Levy Adam R. Officer — D Common Stock 0 0.00 — 8,000 — ↗
2019-06-21 Johnson David Ian Director / Officer — D Common Stock 0 0.00 — 0 — ↗
2019-06-21 Adynxx, Inc. 10% Owner — D Common Stock 0 0.00 — 5,005,211 — ↗

Executive team

Top executives
EBIT / Employee
-150.5K
Shares Outstanding
10.65M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2025-10-30 DEF 14A ↗
2025-10-20 PRE 14A ↗
2025-04-30 DEF 14A ↗
2024-04-29 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-12 8-K ↗
2026-05-07 3 ↗
2026-04-30 8-K ↗
2026-04-30 10-K/A ↗
2026-04-29 SC 13G/A ↗
2026-04-24 8-K ↗
2026-04-21 8-K ↗
2026-03-31 10-K ↗
2026-03-12 SC 13G ↗
2026-03-10 8-K ↗

Executive team

NameTitleCompensationGender
Adam R. Levy Chief Executive Officer, President & Director 388.1K male
Adam E. Drapczuk Interim Chief Financial Officer 248.2K male
Gregory Robb Vice President of Operations — male
ESG Rating
B
MEDICAL - INSTRUMENTS & SUPPLIES
Rank: 6 out of 56
2025
E (Environmental)
67.7 / 64.7
Company / Sector avg.
S (Social)
64.1 / 70.0
Company / Sector avg.
G (Governance)
66.6 / 67.5
Company / Sector avg.
ESG Total
66.1 / 67.4
Company / Sector avg.
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies